MRSA Lung Infection in Cystic Fibrosis: AeroVanc enters Phase III clinical trials

Clinical-stage specialty pharmaceutical company, Savara, Inc. today announced the initiation of the AVAIL study, a Phase III, randomized, double-blind, placebo-controlled study of AeroVanc (vancomycin hydrochloride inhalation powder) for the treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in individuals living with cystic fibrosis (CF). Inhaled antibiotics are standard of care for gram negative Pseudomonas aeruginosa lung infection in individuals living with ["]

The post MRSA Lung Infection in Cystic Fibrosis: AeroVanc enters Phase III clinical trials appeared first on Outbreak News Today.